GlobeNewswire by notified

Biotalys and Biobest Enter into Strategic Partnership to Expand Reach of Novel Biocontrol Solutions

Share

Biotalys’ unique protein-based biocontrol solutions to expand the offer of market leader Biobest in covered crops and berries

Ghent and Westerlo, BELGIUM, and Research Triangle Park (NC), UNITED STATES, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Press release regulated information – inside information

Biotalys and Biobest Enter into Strategic Partnership to Expand Reach of Novel Biocontrol Solutions

Biotalysunique protein-based biocontrol solutions to expand the offer of market leader Biobest in covered crops and berries

Biobest appointed exclusive U.S.distributor of Biotalys’ first biofungicide Evoca™*for all crops and applications

Ghent and Westerlo, BELGIUM,and Research Triangle Park (NC), UNITED STATES 17 December2021, 07:00 CESTBiotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions, and Biobest, a global leader in biocontrol and pollination in covered crops reaching growers in over 65 countries, today announced a long-term strategic partnership. The partnership will grant Biobest access to five protein-based biocontrol solutions developed by Biotalys on its AGROBODY Foundry™ technology platform for Biobest’s global offer in covered crops and berries. In addition, the two companies enter into an exclusive agreement for the distribution of Biotalys’ biofungicide Evoca™ in the United States for all crops and applications, starting in 2022 – pending regulatory approval.

Biobest’s vision is to deliver an innovative and complete range of biological solutions to growers in all major geographical markets,” saidJean-Marc Vandoorne, CEO of Biobest. “Biotalys offers a unique new technology for the development of biodegradable, protein-based biocontrol products which are perfectly fit for the diversification of our offer to covered crop and berry growers and for the challenges these growers face in producing healthy and safe food. We look forward to initiating the offer to growers by adding Biotalys’ biofungicide Evoca™ to our portfolio in the United States upon availability of the product later next year.”

Patrice Sellès, CEO of Biotalys, stated: "We are delighted to have chosen Biobest as our long-term commercial partner for our protein-based biocontrols programs in the covered crops and berry market segments. With its presence on all continents, supporting growers with a wide range of biocontrol solutions, and its innovative approach with novel techniques such as robotics, sensors and other digital supporting tools, Biobest is extremely well positioned to secure the best uptake of our unique technology and candidate products in these selected markets. At the same time, the distribution by Biobest of our very first biocontrol product Evoca™ in the U.S. market is a key milestone for our company and will pave the way for the commercialization of our future products.”

Long-term collaborationagreement

Under the terms of the partnership, Biotalys will offer Biobest a right of first negotiation to come to an exclusive distribution agreement for five protein-based biocontrol programs for use in the global covered crop and berry market during the next 10 years. The product candidates can relate to either the existing or future pipeline.

Each time a product candidate is promoted by Biotalys to the development stage on Biotalys’ AGROBODY Foundry™ technology platform, Biobest will have the rights to access the technology with the aim of adding the end-product to its portfolio of solutions in covered crops and berries. For each of the product candidates being promoted to the development stage, the companies will negotiate a tailored global distribution agreement and associated fees (for the technology and product) taking into account the spectrum, potency and crop applicability of the bio-fungicide, bio-insecticide or bio-bactericide solution involved.

The long-term partnership between Biobest and Biotalys provides that Biotalys will supply the end-products to Biobest for commercialization to growers globally. At a time when the number of crop protection solutions is facing significant challenges from a regulatory and consumer point of view, these growers are in need of more sustainable and safer food protection alternatives to produce healthy and delicious fruits and vegetables. The parties believe that this agreement could generate annual sales in the covered crop and berry space of more than EUR 100 million for both partners combined resulting from the five biocontrol programs.

Biotalys retains full freedom to enter into commercial partnerships for the five biocontrol programs in applications other than covered crops and berries. Biotalys also retains full freedom for R&D partnerships leading to new product candidate programs on any crops and any geographies.

Next to Evoca™, Biotalys’ pipeline at present consists of various bio-fungicide, bio-insecticide and bio-bactericide programs in different research or exploratory stages.

Exclusive distribution agreement for Evoca™ in the United States

Biobest and Biotalys have also signed a distribution agreement under which Biobest will exclusively distribute Evoca™ in the United States for all crops and applications, to calibrate the market as of late 2022, subject to regulatory approval. Evoca™ is Biotalys’ first biofungicide aimed at helping growers to protect crops such as strawberries, grapes and other high-value fruits and vegetables against Botrytis and Powdery Mildew in Integrated Pest Management (IPM) programs.

Biotalys submitted Evoca™ for EPA registration in the United States in December 2020. Following the submission, Biotalys passed both the provided completeness check and the preliminary technical screening. Biotalys expects to receive EPA approval in H2 2022. In April 2021, Biotalys also submitted for approval in California, as this State performs its own in-depth review.

The parties are not disclosing any further financial details.

* Evoca™: Pending Registration. This product is not currently registered for sale or use in the United States , the European Unionor elsewhere and is not being offered for sale.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About Biobest

Biobest, headquartered in Belgium, is a leading player in pollination and biological control. The company reaches out to growers in over 65 countries. Through its subsidiaries, the company has production sites, sales and technical support staff strategically located across the globe for effective worldwide service. Biobest distributors in many countries are key partners with whom the company works very closely to help customers achieve their economic and ecological goals. More information can be found on www.biobestgroup.com.

Biobest is a company majority owned by Floridienne, a Belgian industrial Group holding leading positions in a number of market niches or niche markets, in the sectors of Specialty chemicals & Recycling, Gourmet food and Lifesciences. The Group is listed on the Euronext Brussels Exchange (ISIN BE 0003215143).

For further information, please contact

For Biotalys:

Toon Musschoot, Head of IR & Communication

T: +32 (0)9 274 54 00

E: Toon.Musschoot@biotalys.com

For Biobest:

Jean-Marc Vandoorne-Feys, CEO

T : +32 (0)14 25 79 80

E : jean-marc.vandoorne@biobestgroup.com

For Floridienne:

Thibaut Hofman, Group CFO

T: +32 (0)2 353 05 81

E: tho@floridienne.be

Important Notice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FutureDial Automation Solutions Process Over 231 Million Preowned Mobile Phones Worldwide25.1.2022 14:30:00 CET | Press release

Growing adoption of FutureDial’s robotics and automation software by Wireless Carriers, Third-Party Logistics Providers (3PLs) and Mobile Device Recyclers led to explosive volumes of preowned iPhones and Android Smartphones being processed for resale in 2021 SUNNYVALE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- FutureDial Incorporated continued its commanding lead in providing mobile device processing solutions for Wireless Carriers, Mobile Device Buy-Back & Trade-In Companies, Mobile Phone Recyclers and Third-Party Logistics Providers (3PLs) during the year, announcing that its robotics and automation software solutions have been used by customers in the mobile supply chain to data clear, functionally test and grade a cumulative total of over 231.4 Million pre-owned Android smartphones and iPhones worldwide, for resale on secondary markets. Additionally, the total number of functional tests using FutureDial software and robotics for quality assurance performed on preowned iPhones and A

HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder25.1.2022 14:30:00 CET | Press release

In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also established an office in the United States, furthering global expansion strategy MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for treating stress-axis related Major Depressive Disorder. These license agreements are part of a broader collaboration with the renowned Max-Planck-Society, comprising biomarker patent claims and therapeutic patent claims covering markets in Europe, the U.S., and now Asia, in particular Japan. Utilizing a more personalized approach to discovering new drugs in psychi

Mandalay Resources fortsätter att presentera utmärkta resultat från utvidgningsborrningen i Björkdalsgruvans östra del25.1.2022 14:25:01 CET | Pressemelding

Ådror med synligt guld och höga halter indikerar en uppgradering på djupet i Björkdal TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att meddela en uppdatering om utvidgningsborrningen i de östra delarna av Björkdalsverksamheten i Sverige. Nya borrningshöjdpunkter: Utvidgning av centrala området 47,7 g/t guld över 11,7 m (uppskattad sann bredd ”ETW” 5,85 m) i MU21-052: Inklusive 1 056,0 g/t över 0,40 m;47,5 g/t guld över 6,4 m (ETW 4,11 m) i MU21-047: Inklusive 716,0 g/t över 0,31 m; och507,0 g/t guld över 0,45 m (ETW 0,23 m) i MU21-051. Utvidgningstestning av centrala området 45,5 g/t guld över 2,3 m (ETW 1,15 m) i MU21-028;83,1 g/t guld över 0,4 m (ETW 0,39 m) i MU21-029;8,4 g/t guld över 5,7 m (ETW 5,35 m) in MU21-030; och5,1 g/t guld över 8,0 m (ETW 6,13 m) i MU21-031. Centralt område – Länk till Lake-området 13,2 g/t guld över 1,0 m (ETW 0,94 m) i MU21-028; och19,3 g/t guld över 0,4 m (ETW 0

Exterro Announces Significant Industry Promotion of its Document Review Platform25.1.2022 14:00:00 CET | Press release

Latest Version of Revamped Exterro Review Platform Optimized for Entire Legal Ecosystem; Limited-Time Only Promotion offers up to 6-Months Free Use of Platform PORTLAND, Ore., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Exterro Inc. – the preferred provider of Legal GRC software specifically designed for in-house legal, privacy, and IT teams at Global 2000 and AmLaw 200 organizations – today announced, for a limited-time only, a promotion of up to 6 free months and 5 terabytes of data storage of its Review platform. The promotion coincides with Exterro’s ongoing build out of its Review business unit and updated feature capabilities that are now available to the entire legal ecosystem, including legal service providers, law firms and corporate clients. Furthermore, the promotion of Clay Cocalis to Chief Revenue Officer and the addition of Don McLaughlin, Senior Vice President, Review Software represents the significant investment the company is placing in Exterro Review to ensure greater market s

Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration25.1.2022 14:00:00 CET | Press release

Marimekko Corporation, Stock Exchange Release, 25 January 2022 at 3.00 p.m. Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration Shareholders representing in total approximately 27% of all of Marimekko Corporation’s shares and votes have made a proposal to the Annual General Meeting to be held on 12 April 2022 for the number of members of the Board of Directors, the composition of the Board and its remuneration. Proposal for the number of members of the Board of Directors Shareholders who represent approximately 27% of all of Marimekko Corporation’s shares and votes have informed the company that they propose to the Annual General Meeting that six (6) members be elected to the Board of Directors. Proposal for the composition of the Board of Directors The above-mentioned shareholders have also informed the company that they propose that Carol Chen, Mika Ihamuotila, Mikko-Heikki Inkeroinen and

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS25.1.2022 11:07:00 CET | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2022-01-25Loan2311Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,357 Volume bought, SEK mln500 Number of bids4 Number of accepted bids1 Average yield0.067 %Lowest accepted yield0.067 %Highest yield0.067 %% accepted at lowest yield 100.00 Auction date2022-01-25Loan2611Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,699 Volume bought, SEK mln500 Number of bids6 Number of accepted bids3 Average yield0.725 %Lowest accepted yield0.722 %Highest yield0.730 %% accepted at lowest yield 54.55 Auction date2022-01-25Loan2805Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,462 Volume bought, SEK mln500 Number of bids11 Number of accepted bids4 Average yield0.957 %Lowest accepted yield0.954 %Highest yield0.970 %% accepted at lowest yield 64.